The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
telephone:
01413308410
email:
Samantha.Miller@glasgow.ac.uk
B4.05, Sir Graeme Davies Building, 120 University Place, Glasgow, G12 8TA
Goodyear, C. S. et al. (2024) Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Rheumatology, 6(6), e339-e351. (doi: 10.1016/S2665-9913(24)00065-1) (PMID:38734019)
Goodyear, C. S. et al. (2024) Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Rheumatology, 6(6), e339-e351. (doi: 10.1016/S2665-9913(24)00065-1) (PMID:38734019)